Table 1 Clinicopathological characteristics of 147 triple-negative breast cancer (TNBC) patients with normal or abnormal electrocardiography (ECG)
Characteristic | Normal ECG group | Abnormal ECG group | P value |
|---|---|---|---|
Total [cases (%)] | 46 (31.3) | 101 (68.7) | – |
Age [years, median (range)] | 51 (30–75) | 50 (32–72) | 0.731 |
Baseline heart rate [bpm, mean ± SD] | 75.1 ± 10.7 | 75.3 ± 11.7 | 0.931 |
Disease-free survival [months, median (range)] | 64.3 (7.7–183.2) | 58.6 (3.6–181.7) | 0.473 |
Hypertension [cases (%)] | 5 (10.9) | 17 (16.8) | 0.490 |
Diabetes [cases (%)] | 1 (2.2) | 7 (6.9) | 0.250 |
Smoking [cases (%)] | 2 (4.3) | 5 (5.0) | 0.874 |
Excessive alcohol consumption [cases (%)] | 1 (2.2) | 16 (15.8) | 0.034 |
Family history of heart disease [cases (%)] | 4 (8.7) | 7 (6.9) | 0.969 |
Chemotherapy [cases (%)] | 1.000 | ||
Neoadjuvant | 3 (6.5) | 5 (5.0) | |
Adjuvant | 43 (93.5) | 96 (95.0) | |
Drug uses [cases (%)] | |||
Anthracyclines | 22 (47.8) | 67 (66.3) | 0.033 |
Cyclophosphamide | 24 (52.2) | 57 (56.4) | 0.630 |
Paclitaxel | 20 (43.5) | 42 (41.6) | 0.829 |
Docetaxel | 19 (41.3) | 40 (39.6) | 0.845 |
Carboplatin | 16 (34.8) | 27 (26.7) | 0.320 |
5-Fluorouracil | 1 (2.2) | 4 (4.0) | 0.949 |
Chemotherapy regimens [cases (%)] | 0.242 | ||
Anthracycline-based | 6 (13.0) | 16 (15.8) | |
Taxane-based | 23 (50.0) | 33 (32.7) | |
Anthracycline–taxane-based | 16 (34.8) | 50 (49.5) | |
Others | 1 (2.2) | 2 (2.0) | |